-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Furmonertinib Mesylate in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Furmonertinib Mesylate in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Furmonertinib Mesylate in Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Talditercept Alfa in Spinal Muscular Atrophy (SMA)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Talditercept Alfa in Spinal Muscular Atrophy (SMA) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Talditercept Alfa in Spinal Muscular Atrophy (SMA) Drug...
-
Sector Analysis
NewInternet from Sky – Can LEO Satellites Transform the Future of Connectivity? (Vol. 2)
LEO Satellites - Internet from Sky Report Overview The surge in low earth orbit (LEO) satellite projects indicates a global trend toward diversifying internet coverage. This trend focuses on bridging the digital divide and enhancing real-time data transmission for various sectors, including aerospace and defense. LEOs provide a competitive edge due to their lower latency, and their increasing deployment signifies a pivotal shift toward a more connected future. LEOs are more secure than terrestrial networks as communication happens in space...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Maveropepimut-s in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Maveropepimut-s in Epithelial Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Maveropepimut-s in Epithelial Ovarian Cancer Drug Details: Maveropepimut-s (DPX-Survivac) is...
-
Product Insights
NewQ-linea AB Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Q-linea AB Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Q-linea AB (Q-linea) is a medical technology company that develops solutions for the diagnosis of infectious diseases. The company offers ASTar, an automated system for antibiotic susceptibility testing; and ASTar kits such as Cartridges and AST discs. It also offers ASTar Instrument and ASTar BC G-kit. Q-linea is headquartered in Uppsala, Stockholm, Sweden. GlobalData's Medical Devices company profile report, “Q-linea...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MT-6042 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MT-6042 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MT-6042 in Non-Small Cell Lung Cancer Drug Details: MT-6042...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AST-001 in Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AST-001 in Leukemia Drug Details: AST-001 is under development for treatment of brain tumor, lung...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AST-001 in Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AST-001 in Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AST-001 in Glioma Drug Details: AST-001 is under development for treatment of brain...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AST-001 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AST-001 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AST-001 in Pancreatic Cancer Drug Details: AST-001 is under development for treatment...